Thermo Fisher Scientific Inc. (0R0H.L)
USD 523.04
(-1.93%)
USD 523.04
(-1.93%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 34.91 Billion USD | 1.24% |
| 2022 | 34.48 Billion USD | -1.1% |
| 2021 | 34.87 Billion USD | 60.43% |
| 2020 | 21.73 Billion USD | 22.44% |
| 2019 | 17.75 Billion USD | -6.52% |
| 2018 | 18.99 Billion USD | -9.61% |
| 2017 | 21 Billion USD | 26.34% |
| 2016 | 16.62 Billion USD | 32.74% |
| 2015 | 12.52 Billion USD | -13.99% |
| 2014 | 14.56 Billion USD | 38.87% |
| 2013 | 10.48 Billion USD | 47.2% |
| 2012 | 7.12 Billion USD | 1.37% |
| 2011 | 7.02 Billion USD | 6542.72% |
| 2010 | 105.8 Million USD | -95.15% |
| 2009 | 2.18 Billion USD | 6.08% |
| 2008 | 2.05 Billion USD | -6.24% |
| 2007 | 2.19 Billion USD | -17.6% |
| 2006 | 2.66 Billion USD | 344.91% |
| 2005 | 598.76 Million USD | 148.36% |
| 2004 | 241.08 Million USD | -12.49% |
| 2003 | 275.49 Million USD | -70.56% |
| 2002 | 935.82 Million USD | 18.91% |
| 2001 | 787 Million USD | -51.09% |
| 2000 | 1.6 Billion USD | -4.17% |
| 1999 | 1.67 Billion USD | -22.27% |
| 1998 | 2.16 Billion USD | 12.5% |
| 1997 | 1.92 Billion USD | 12.68% |
| 1996 | 1.7 Billion USD | 39.44% |
| 1995 | 1.22 Billion USD | 7.87% |
| 1994 | 1.13 Billion USD | 63.37% |
| 1993 | 693.4 Million USD | 34.33% |
| 1992 | 516.2 Million USD | 98.61% |
| 1991 | 259.9 Million USD | 19.88% |
| 1990 | 216.8 Million USD | 8.62% |
| 1989 | 199.6 Million USD | 24.91% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 35.31 Billion USD | -0.26% |
| 2024 Q1 | 35.6 Billion USD | 1.98% |
| 2024 Q2 | 35.4 Billion USD | -0.57% |
| 2023 Q1 | 35.25 Billion USD | 2.23% |
| 2023 Q3 | 35.28 Billion USD | 3.75% |
| 2023 FY | 34.91 Billion USD | 1.24% |
| 2023 Q2 | 34 Billion USD | -3.54% |
| 2023 Q4 | 34.91 Billion USD | -1.04% |
| 2022 Q1 | 33.25 Billion USD | -4.63% |
| 2022 FY | 34.48 Billion USD | -1.1% |
| 2022 Q4 | 34.48 Billion USD | 18.27% |
| 2022 Q3 | 29.16 Billion USD | -3.64% |
| 2022 Q2 | 30.26 Billion USD | -9.01% |
| 2021 Q3 | 21.7 Billion USD | 15.6% |
| 2021 Q4 | 34.87 Billion USD | 60.64% |
| 2021 Q1 | 18.64 Billion USD | -14.22% |
| 2021 FY | 34.87 Billion USD | 60.43% |
| 2021 Q2 | 18.77 Billion USD | 0.71% |
| 2020 Q2 | 21.31 Billion USD | 6.73% |
| 2020 Q3 | 21.09 Billion USD | -1.03% |
| 2020 Q4 | 21.73 Billion USD | 3.04% |
| 2020 FY | 21.73 Billion USD | 22.44% |
| 2020 Q1 | 19.96 Billion USD | 12.49% |
| 2019 Q4 | 17.75 Billion USD | 4.1% |
| 2019 FY | 17.75 Billion USD | -6.52% |
| 2019 Q1 | 18.14 Billion USD | -4.43% |
| 2019 Q3 | 17.05 Billion USD | -10.44% |
| 2019 Q2 | 19.04 Billion USD | 4.92% |
| 2018 Q3 | 18.77 Billion USD | -3.33% |
| 2018 Q4 | 18.99 Billion USD | 1.15% |
| 2018 FY | 18.99 Billion USD | -9.61% |
| 2018 Q1 | 20.93 Billion USD | -0.34% |
| 2018 Q2 | 19.42 Billion USD | -7.24% |
| 2017 Q1 | 17.07 Billion USD | 2.66% |
| 2017 FY | 21 Billion USD | 26.34% |
| 2017 Q3 | 21.99 Billion USD | 30.94% |
| 2017 Q4 | 21 Billion USD | -4.48% |
| 2017 Q2 | 16.79 Billion USD | -1.61% |
| 2016 Q1 | 15.03 Billion USD | 20.03% |
| 2016 Q2 | 14.14 Billion USD | -5.91% |
| 2016 Q3 | 18.91 Billion USD | 33.68% |
| 2016 Q4 | 16.62 Billion USD | -12.08% |
| 2016 FY | 16.62 Billion USD | 32.74% |
| 2015 Q3 | 13.31 Billion USD | -5.07% |
| 2015 FY | 12.52 Billion USD | -13.99% |
| 2015 Q1 | 14.85 Billion USD | 2.01% |
| 2015 Q2 | 14.02 Billion USD | -5.61% |
| 2015 Q4 | 12.52 Billion USD | -5.9% |
| 2014 Q4 | 14.56 Billion USD | 0.6% |
| 2014 Q3 | 14.47 Billion USD | -7.06% |
| 2014 Q2 | 15.57 Billion USD | -10.28% |
| 2014 Q1 | 17.36 Billion USD | 65.56% |
| 2014 FY | 14.56 Billion USD | 38.87% |
| 2013 Q1 | 7.11 Billion USD | -0.08% |
| 2013 Q4 | 10.48 Billion USD | 47.47% |
| 2013 Q3 | 7.11 Billion USD | -0.04% |
| 2013 Q2 | 7.11 Billion USD | -0.06% |
| 2013 FY | 10.48 Billion USD | 47.2% |
| 2012 FY | 7.12 Billion USD | 1.37% |
| 2012 Q4 | 7.12 Billion USD | -4.66% |
| 2012 Q3 | 7.47 Billion USD | 14.39% |
| 2012 Q1 | 6.67 Billion USD | -5.02% |
| 2012 Q2 | 6.53 Billion USD | -2.14% |
| 2011 FY | 7.02 Billion USD | 6542.72% |
| 2011 Q4 | 7.02 Billion USD | -1.48% |
| 2011 Q3 | 7.13 Billion USD | 77.14% |
| 2011 Q2 | 4.02 Billion USD | -6.35% |
| 2011 Q1 | 4.3 Billion USD | 101.22% |
| 2010 Q1 | 2.07 Billion USD | -4.78% |
| 2010 FY | 105.8 Million USD | -95.15% |
| 2010 Q3 | 107.7 Million USD | -94.96% |
| 2010 Q4 | 2.13 Billion USD | 1884.31% |
| 2010 Q2 | 2.13 Billion USD | 2.87% |
| 2009 FY | 2.18 Billion USD | 6.08% |
| 2009 Q2 | 2.04 Billion USD | 0.22% |
| 2009 Q1 | 2.04 Billion USD | -0.88% |
| 2009 Q4 | 2.18 Billion USD | 7.31% |
| 2009 Q3 | 2.03 Billion USD | -0.48% |
| 2008 Q2 | 2.18 Billion USD | -0.31% |
| 2008 Q1 | 2.19 Billion USD | 0.07% |
| 2008 FY | 2.05 Billion USD | -6.24% |
| 2008 Q3 | 2.18 Billion USD | -0.37% |
| 2008 Q4 | 2.05 Billion USD | -5.66% |
| 2007 Q2 | 2.2 Billion USD | -6.27% |
| 2007 Q1 | 2.34 Billion USD | -11.79% |
| 2007 FY | 2.19 Billion USD | -17.6% |
| 2007 Q3 | 2.2 Billion USD | -0.08% |
| 2007 Q4 | 2.19 Billion USD | -0.25% |
| 2006 FY | 2.66 Billion USD | 344.91% |
| 2006 Q3 | 538.54 Million USD | -15.72% |
| 2006 Q1 | 560.45 Million USD | -6.4% |
| 2006 Q2 | 639 Million USD | 14.01% |
| 2006 Q4 | 2.66 Billion USD | 394.67% |
| 2005 Q4 | 598.76 Million USD | -6.37% |
| 2005 Q1 | 226.41 Million USD | -6.09% |
| 2005 FY | 598.76 Million USD | 148.36% |
| 2005 Q2 | 701.19 Million USD | 209.7% |
| 2005 Q3 | 639.51 Million USD | -8.8% |
| 2004 Q2 | 259.6 Million USD | -4.9% |
| 2004 Q1 | 272.98 Million USD | -0.91% |
| 2004 Q3 | 243.81 Million USD | -6.08% |
| 2004 FY | 241.08 Million USD | -12.49% |
| 2004 Q4 | 241.08 Million USD | -1.12% |
| 2003 FY | 275.49 Million USD | -70.56% |
| 2003 Q1 | 681.94 Million USD | -27.13% |
| 2003 Q2 | 455.37 Million USD | -33.22% |
| 2003 Q3 | 255 Million USD | -44.0% |
| 2003 Q4 | 275.49 Million USD | 8.03% |
| 2002 Q1 | 1.14 Billion USD | -8.68% |
| 2002 Q2 | 1.1 Billion USD | -3.4% |
| 2002 Q4 | 935.82 Million USD | -10.28% |
| 2002 Q3 | 1.04 Billion USD | -5.87% |
| 2002 FY | 935.82 Million USD | 18.91% |
| 2001 FY | 787 Million USD | -51.09% |
| 2001 Q4 | 1.25 Billion USD | -13.56% |
| 2001 Q3 | 1.45 Billion USD | -7.13% |
| 2001 Q2 | 1.56 Billion USD | -1.67% |
| 2001 Q1 | 1.59 Billion USD | -2.5% |
| 2000 Q4 | 1.63 Billion USD | -2.58% |
| 2000 Q1 | 1.83 Billion USD | -0.11% |
| 2000 Q2 | 1.71 Billion USD | -6.63% |
| 2000 Q3 | 1.67 Billion USD | -2.43% |
| 2000 FY | 1.6 Billion USD | -4.17% |
| 1999 Q2 | 2.15 Billion USD | -1.19% |
| 1999 Q4 | 1.84 Billion USD | -17.41% |
| 1999 Q3 | 2.22 Billion USD | 3.39% |
| 1999 Q1 | 2.18 Billion USD | 14.3% |
| 1999 FY | 1.67 Billion USD | -22.27% |
| 1998 Q2 | 2.06 Billion USD | -2.22% |
| 1998 Q3 | 2.01 Billion USD | -2.51% |
| 1998 Q1 | 2.11 Billion USD | 10.21% |
| 1998 FY | 2.16 Billion USD | 12.5% |
| 1998 Q4 | 1.9 Billion USD | -5.35% |
| 1997 Q2 | 1.64 Billion USD | -7.67% |
| 1997 Q3 | 1.94 Billion USD | 17.83% |
| 1997 Q4 | 1.92 Billion USD | -1.18% |
| 1997 FY | 1.92 Billion USD | 12.68% |
| 1997 Q1 | 1.78 Billion USD | 4.81% |
| 1996 Q3 | 1.56 Billion USD | -13.77% |
| 1996 Q4 | 1.7 Billion USD | 8.88% |
| 1996 FY | 1.7 Billion USD | 39.44% |
| 1996 Q1 | 1.78 Billion USD | 44.96% |
| 1996 Q2 | 1.81 Billion USD | 1.79% |
| 1995 Q3 | 1.17 Billion USD | 0.3% |
| 1995 Q1 | 1.11 Billion USD | -1.22% |
| 1995 Q2 | 1.17 Billion USD | 4.74% |
| 1995 Q4 | 1.23 Billion USD | 4.64% |
| 1995 FY | 1.22 Billion USD | 7.87% |
| 1994 FY | 1.13 Billion USD | 63.37% |
| 1994 Q3 | 1.12 Billion USD | -4.66% |
| 1994 Q4 | 1.13 Billion USD | 0.6% |
| 1994 Q2 | 1.18 Billion USD | 39.43% |
| 1994 Q1 | 847 Million USD | 22.15% |
| 1993 Q2 | 497.4 Million USD | -2.11% |
| 1993 Q1 | 508.1 Million USD | -1.57% |
| 1993 Q4 | 693.4 Million USD | 25.3% |
| 1993 FY | 693.4 Million USD | 34.33% |
| 1993 Q3 | 553.4 Million USD | 11.26% |
| 1992 Q1 | 253.4 Million USD | -2.5% |
| 1992 Q2 | 242.5 Million USD | -4.3% |
| 1992 Q4 | 516.2 Million USD | 4.49% |
| 1992 FY | 516.2 Million USD | 98.61% |
| 1992 Q3 | 494 Million USD | 103.71% |
| 1991 Q1 | 283.4 Million USD | 30.72% |
| 1991 Q3 | 270 Million USD | -0.59% |
| 1991 Q4 | 259.9 Million USD | -3.74% |
| 1991 FY | 259.9 Million USD | 19.88% |
| 1991 Q2 | 271.6 Million USD | -4.16% |
| 1990 Q3 | 227.7 Million USD | 18.16% |
| 1990 FY | 216.8 Million USD | 8.62% |
| 1990 Q1 | 169.5 Million USD | -15.08% |
| 1990 Q2 | 192.7 Million USD | 13.69% |
| 1990 Q4 | 216.8 Million USD | -4.79% |
| 1989 FY | 199.6 Million USD | 24.91% |
| 1989 Q3 | 194.3 Million USD | 0.0% |
| 1989 Q4 | 199.6 Million USD | 2.73% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -95468.754% |
| Dynavax Technologies Corporation | 256.91 Million USD | -13490.929% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -83982.645% |
| Perrigo Company plc | 4.07 Billion USD | -757.195% |
| Illumina, Inc. | 2.26 Billion USD | -1443.634% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3491600.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | -265.47% |
| IQVIA Holdings Inc. | 14.23 Billion USD | -145.359% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -19995.768% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -1191.835% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -129270.137% |
| Waters Corporation | 2.35 Billion USD | -1382.352% |
| Biogen Inc. | 7.33 Billion USD | -375.825% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -91536.049% |
| Evolus, Inc. | 126.54 Million USD | -27492.338% |
| Adicet Bio, Inc. | 17.7 Million USD | -197137.756% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -80788.178% |
| bluebird bio, Inc. | 330.32 Million USD | -10470.467% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -6354.791% |
| FibroGen, Inc. | 170.45 Million USD | -20384.585% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -1176.673% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -167093.124% |
| Homology Medicines, Inc. | 44.05 Million USD | -79159.545% |
| Geron Corporation | 85.89 Million USD | -40548.902% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | -1356.079% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -7745.477% |
| Myriad Genetics, Inc. | 145 Million USD | -23980.69% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -2771090.476% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -30171.531% |
| Zoetis Inc. | 6.8 Billion USD | -413.259% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -793107.633% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -1510.734% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -2979.44% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -4219.273% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -96029.174% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -2302.206% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -60234.877% |
| Verastem, Inc. | 41.55 Million USD | -83921.946% |
| Nektar Therapeutics | 230.4 Million USD | -15054.882% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -18635.11% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1135781.588% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -2399.771% |
| OPKO Health, Inc. | 326.56 Million USD | -10592.238% |
| Exelixis, Inc. | 189.94 Million USD | -18282.787% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -8050.56% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -23123741.06% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -25127.406% |
| Imunon, Inc. | 1.13 Million USD | -3064695.448% |
| Blueprint Medicines Corporation | 774.12 Million USD | -4410.529% |
| Insmed Incorporated | 1.2 Billion USD | -2800.098% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -2228.968% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -61170.794% |
| TG Therapeutics, Inc. | 110.79 Million USD | -31414.96% |
| Incyte Corporation | 38.28 Million USD | -91098.057% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -3879.145% |